Journal of Antimicrobial Chemotherapy (1999) 43, Suppl. B, 1-11
© 1999 The British Society for Antimicrobial Chemotherapy
A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new `respiratory quinolones'
Departments of Clinical Microbiology and Pathology, Saskatoon District Health, St Paul's Hospital (Grey Nuns'), Royal University Hospital and the University of Saskatchewan, Saskatoon, Saskatchewan, S7N 0W8, Canada
The efficacies of many antimicrobial agents are being threatened by a global increase in the numbers of resistant bacterial pathogens—microorganisms that were once susceptible to some of these agents. In particular, antimicrobial resistance amongst strains of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae has limited the usefulness of first-line agents in some clinical settings. Quinolones were introduced in the 1980s and represented a significant therapeutic advancement in the treatment of patients with infectious diseases. While these compounds possessed potent in-vitro activities against a wide range of Gram-negative pathogens, their activities against some Gram-positive and `atypical' pathogens remained borderline. Further advancement in the development of quinolones has overcome some of these problems. The `respiratory quinolones' represent a new generation within this class of molecules and comprise compounds possessing broad spectrum activities against Gram-negative, Gram-positive and atypical pathogens. This review will focus on the in-vitro activities of five new respiratory quinolones (gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin), ciprofloxacin and six non-quinolone agents (azithromycin, clarithromycin, amoxycillin, co-amoxiclav, cefuroxime and co-trimoxazole) against a range of bacterial and atypical pathogens, including those that are now resistant to several of these compounds.
* Corresponding address. Department of Clinical Microbiology, Royal University Hospital, 103 Hospital Drive, Saskatoon, Saskatchewan, S7N 0W8, Canada. Tel: +1-306-655-6943; Fax: +1-306-655-6947; E-mail: blondeauj{at}sdh.sk.ca
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Silley, B. Stephan, H. A. Greife, and A. Pridmore Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats J. Antimicrob. Chemother., November 1, 2007; 60(5): 999 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Fuller and D. M. Marcus Vitreous and Aqueous Penetration of Orally Administered Gatifloxacin in Humans Arch Ophthalmol, September 1, 2004; 122(9): 1408 - 1409. [Full Text] [PDF]
|
|